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The endocannabinoid system has been involved in the regulation of anxiety, and proposed as an inhibitory modulator of neu-
ronal, behavioral and adrenocortical responses to stressful stimuli. Brain regions such as the amygdala, hippocampus and cortex,
which are directly involved in the regulation of emotional behavior, contain high densities of cannabinoid CB1 receptors. Mutant
mice lacking CB1 receptors show anxiogenic and depressive-like behaviors as well as an altered hypothalamus pituitary adrenal
axis activity, whereas enhancement of endocannabinoid signaling produces anxiolytic and antidepressant-like eﬀects. Genetic and
pharmacological approaches also support an involvement of endocannabinoids in extinction of aversive memories. Thus, the en-
docannabinoid system appears to play a pivotal role in the regulation of emotional states. Endocannabinoids have emerged as
mediators of short- and long- term synaptic plasticity in diverse brain structures. Despite the fact that most of the studies on this
ﬁeld have been performed using in vitro models, endocannabinoid-mediated plasticity might be considered as a plausible can-
didate underlying some of the diverse physiological functions of the endogenous cannabinoid system, including developmental,
aﬀective and cognitive processes. In this paper, we will focus on the functional relevance of endocannabinoid-mediated plasticity
within the framework of emotional responses. Alterations of the endocannabinoid system may constitute an important factor in
the aetiology of certain neuropsychiatric disorders, and, in turn, enhancers of endocannabinoid signaling could represent a poten-
tial therapeutical tool in the treatment of both anxiety and depressive symptoms.
Copyright © 2007 Mar´ ıa-Paz Viveros et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Fear is an adaptive component of the acute stress response
to potentially dangerous stimuli which threaten the integrity
of the individual. However, when disproportional in inten-
sity, chronic, irreversible, and/or not associated with any ac-
tual risk, it constitutes a maladaptive response and may be
symptomatic of an anxiety-related neuropsychiatric disor-
der such as generalized anxiety, phobia, or post-traumatic
stress disorder (PTSD), among others. A diversity of mech-
anisms, including GABAergic, serotonergic, and noradren-
ergic systems, appears to be involved in the regulation of
anxious states which may contribute to an appropriate emo-
tional response to aversive events [1]. In the recent years, an
increasing interest in the endocannabinoid system has arisen
as part of the complex circuitry that regulates anxiety and as
a crucial mediator of emotional learning. Brain distribution
of cannabinoid CB1 receptors is consistent with an involve-
ment of this system in the regulation of emotional reactivity.
Indeed, CB1 receptors are highly expressed in brain struc-
tures such as the amygdala, hippocampus, anterior cingulate
cortex,andprefrontalcortex[2–8],keyregionsintheregula-
tion of emotional responses. Moreover, the cannabinoid CB1
agonist CP 55,940 increased Fos immunoreactivity in brain
structures known to be involved in anxiety and fear-related
responses such as the central nucleus of the amygdala, the
periaqueductal gray, and the paraventricular nucleus (PVN)
of the hypothalamus [9].
Depression is a mood disorder in which the prevailing
emotional mood is distorted or inappropriate to the circum-
stances. There are important links between chronic stress
and depression. Upon exposure to acute stressful stimuli,
the organism initiates a series of neuroendocrine short-term
responses that are beneﬁcial in terms of adaptation. How-
ever, exposure to chronic, unavoidable situations of stress
may have deleterious consequences, including endocrine,
emotional, and cognitive alterations associated with neu-
ropsychiatric disorders such as depression. In this context,2 Neural Plasticity
hyperactivity of the hypothalamus-pituitary-adrenal (HPA)
axiswithincreasedglucocorticoidslevelsappearstobelinked
to major depression [10, 11]. There is evidence for an in-
volvement of the endocannabinoid system in the regulation
of neural, behavioral, and endocrine responses to aversive
stimuli [12, 13] and it has been suggested that stress-induced
dysregulation of speciﬁc components of the endocannabi-
noid system might be associated with deﬁcits in behavioral
ﬂexibility that can be manifested in stress-related disorders
such as PTSD and depression [14].
Endocannabinoids have been shown to act as retro-
grade transmitters at the synaptic level. Though the exact
role of retrograde endocannabinoid signaling in vivo is not
fully clariﬁed yet, it is likely that by this mechanism en-
docannabinoids play important roles in synaptic transmis-
sion and plasticity, including modulation of emotional re-
sponses. Indeed, endocannabinoids have recently emerged
as one of the most thoroughly investigated, and widely ac-
cepted, classes of retrograde messengers in the brain [15].
Cannabinoid-induced neuroplasticity may underlie diverse
physiological functions modulated by the endocannabinoid
system, that is, pain [16] and memory [17]. Synaptic plastic-
ity within the amygdala appears to play a crucial role in ac-
quisition, storage, and extinction of aversive memories, ba-
sic neural processes that serve adaptive behaviors, and the
endocannabinoid system has emerged as a crucial mediator
of such neuroplasticity-related phenomena. Marsicano et al.
[18, 19] proposed that endocannabinoids facilitate extinc-
tion of aversive memories through their selective inhibitory
eﬀects on local inhibitory networks in the amygdala, pro-
viding evidence for a functional role of endocannabinoid
release-based synaptic plasticity. Apart from the amygdala,
there are some other brain areas that have been postulated as
substrates for cannabinoid-induced neural plasticity such as
thehippocampusandthehypothalamuswherecannabinoid-
dependent synaptic plasticity is involved in the regulation of
the stress-response system [17, 20]. Pharmacological modu-
lation of the endocannabinoid system has been proposed as
a novel potential therapeutical strategy for the treatment of
anxiety disorders and depression [21], and therapeutic inter-
ventions directed at normalization of the HPA system [11]
might potentially include modulation of endocannabinoid
signaling.
2. THE ENDOCANNABINOID SYSTEM AND
CANNABINOID-RELATED COMPOUNDS
The endocannabinoid system includes the cannabinoid re-
ceptors, the endogenous lipid ligands (endocannabinoids),
and the enzymatic machinery for their synthesis and in-
activation. Endocannabinoids are important neuromodula-
tors that appear to be involved in a plethora of physiologi-
c a lp r o c e s s e ss u c ha sm o d u l a t i o no fn o c i c e p t i o n ,r e g u l a t i o n
of motor activity, cognitive processes, neuroprotection, im-
mune function and inﬂammatory responses, antiprolifera-
tive actions in tumoral cells, control of cardiovascular sys-
tem, and neurodevelopment, among others [22–29]. No-
tably, the endocannabinoid system appears to be critically
involved in the maintenance of homeostasis [28, 30]. In this
review, we aim to highlight its function as a stress-recovery
system.
Endocannabinoids are polyunsaturated fatty acid deriva-
tives. The ethanolamide of arachidonic acid anandamide
(AEA)and2-arachidonoylglycerol(2-AG)arethemoststud-
ied endocannabinoids and have been implicated in a wide
range of physiological and pathological processes. Other
molecules such as 2-arachidonyl-glyceryl ether (noladin,
2-AGE), O-arachidonoyl-ethanolamine (virhodamine), and
N-arachidonoyl-dopamine (NADA) have been discovered
more recently. The anabolic and catabolic pathways for
AEA and 2-AG appear to rely on very complex enzymatic
cascades and are in the progress of being elucidated. In
brief, the enzime N-acylphosphatidylethanolamine-speciﬁc
phospholipase D (NAPE-PLD) synthesizes AEA from N-
arachidonoylphosphatidylethanolamine (NArPE), whereas
the diacylglycerol lipase (DAGL) generates 2-AG from dia-
cylglycerol (DAG) substrates. Due to their lipophilic nature,
endocannabinoids cannot be stored in vesicles. It is widely
accepted that, unlike other mediators, the endocannabinoids
are synthesized and released on demand, in response to di-
verse physiological and pathological stimuli, and appear to
exert important actions as retrograde messengers. Endo-
cannabinoid inactivating mechanisms include cellular reup-
take and hydrolysis. AEA appears to be taken up by sev-
eral cell types at least in part via a facilitated transport
mechanism, known as the anandamide membrane trans-
porter (AMT), which can also transport 2-AG intracellu-
larly. Though this putative transporter has not been iso-
lated or cloned yet, there are compounds that are consid-
ered as inhibitors of cellular uptake. A fatty acid amide
hydrolase (FAAH) is the main AEA hydrolase, whereas a
monoacylglycerol lipase (MAGL) is critical in degrading 2-
AG. It is important to take into consideration that the ac-
tions of endocannabinoids are considered to be spatially
and temporally restricted. Therefore, the eﬀects of exoge-
nously applied cannabinoids, which lack such selectivity, do
not necessarily mimic physiological functions of the endo-
cannabinoid system [26, 28]. Compounds that enhance en-
docannabinoid signaling by inhibiting endocannabinoid re-
uptake (e.g., VDM11, OMDM-1, OMDM-2, UCM707) or
by degradation (e.g., the FAAH inhibitors URB597, AM374,
or N-arachidonoyl-serotonin) are widely used in preclinical
studies and appear to have a potential therapeutical interest.
A profound discussion of biochemical aspects of the endo-
cannabinoid system is beyond the scope of this paper, but
the reader can ﬁnd comprehensive excellent reviews (e.g.,
[27, 28, 31–35]) as well as recent papers on speciﬁc aspects
such as alternative biosynthetic pathways for endocannabi-
noids [36, 37] and endocannabinoid membrane transport
[38].
Cannabinoids mainly exert their pharmacological eﬀects
by the activation of speciﬁc membrane receptors. Mam-
malian tissues contain at least two types of cannabinoid re-
ceptors, CB1 and CB2, which are metabotropic receptors
coupled to G-proteins of the Gi/o type. CB1 receptors areMar´ ıa-Paz Viveros et al. 3
localized mainly in the central nervous system, but are also
present in a variety of peripheral tissues; they are among the
most abundant andwidely distributed G-protein coupled re-
ceptors in the brain. Transduction systems include inhibi-
tion of adenylyl cyclase and of certain voltage-sensitive cal-
cium channels (predominately, those found presynaptically)
and activation of inwardly-rectifying potassium channels
and mitogen-activated protein (MAP) kinase [39]. Autora-
diographic and immunohistochemical studies have shown
that CB1 receptors are expressed in multiple brain areas, in-
cluding the olfactory bulb, neocortex, pyriform cortex, hip-
pocampus, amygdala, basal ganglia, thalamic and hypothala-
mic nuclei, cerebellar cortex and brainstem nuclei. In partic-
ular, a high density of CB1 receptors is found in cortical and
limbic regions associated with emotional responses. The lev-
els of expression vary among the various brain regions and
neuronal subpopulations, and there is apparently no strict
correlation between levels of expression and receptor func-
tionality. Thus, the activity of cannabinoids at CB1 receptor
depends not only on the relative receptor density but also on
other factors such as receptor coupling eﬃciency [2, 28, 40–
43]. It has been widely accepted that cannabinoids regulate
GABA release by activation of CB1 receptor type, and the
highest levels of CB1 cannabinoid receptors are found on the
terminals of cholecystokinin-positive GABAergic interneu-
rons [44, 45]. On the other hand, the expression of CB1 re-
ceptor in glutamatergic neurons has been vigorously debated
in recent years. In fact, some authors proposed that a novel
non-CB1/non-CB2 cannabinoid-sensitive receptor could be
responsible for the inhibition of glutamatergic neurotrans-
mission [46, 47]. However, it has been now well established
that functional cannabinoid CB1 receptors are present on
glutamatergicterminalsofthehippocampalformation,colo-
calizing with vesicular glutamate transporter 1 [48], as well
as in other cortical areas (see, e.g., [26, 49, 50]). These evi-
dences do not exclude that a non-CB1 receptor might exist
in the brain, but there is to date no molecular evidence for
such novel receptor.
Cannabinoid CB2 receptors are mostly peripherally lo-
cated on immunological tissues, and therefore implicated
in immunological functions. However, they have also been
foundwithinthecentralnervoussystemonneuronsandglial
cells with their expression mainly related to conditions of
inﬂammation [51–53]. More recent immunohistochemical
analyses have revealed immunostaining for CB2 receptors in
apparent neuronal and glial processes in diverse rat brain ar-
eas, including cerebellum and hippocampus [54, 55]. These
results change the classical view of peripherally located CB2
receptors and suggest broader functional roles for these re-
ceptors.
It has been shown that some of the eﬀects of anan-
damide are mediated by the transient receptor potential
vanilloid type-1 channel (TRPV1), formerly called vanil-
loid receptor VR1 [39]. These receptors have been tradi-
tionally known for their function in sensory nerves where
they mediate perception of inﬂammatory and thermal pain,
but they are also expressed within the brain contributing to
other important physiological functions. Co-expression of
cannabinoid CB1 and TRPV1 receptors was found by us-
ing immunoﬂuorescence techniques in diverse brain areas
involved in the regulation of emotional responses. In par-
ticular, within the hippocampus, CB1/TRPV1 was detected
on cell bodies of many pyramidal neurons throughout the
CA1–CA3 subﬁelds and in the molecular layer of dentate
gyrus [56]. Interestingly, TRPV1 knockout mice (TRPV1-
KO) showed less anxiety-related behavior in the light-dark
test and in the elevated plus-maze than their wild-type lit-
termates as well as less freezing to a tone after auditory
fear conditioning and stress sensitization. TRPV1-KO also
showed impaired hippocampus-dependent contextual fear
together with a decrease in long-term potentiation (LTP)
in the Schaﬀer collateral-commissural pathway to CA1 hip-
pocampalneurons.Thesedataprovideﬁrstevidenceforfear-
promoting eﬀects of TRPV1 with respect to both innate and
conditioned fear and for a decisive role of this receptor in
synaptic plasticity [57]. Collectively, these ﬁndings open new
avenues for the study of possible functional relationships
between CB1 and TRPV1 receptors, in particular regarding
stress, fear, and anxiety responses.
Recently, an additional G-protein-coupled receptor
(GPCR) GPR55 has been proposed as a possible new canna-
binoid receptor that might play a physiological role in lipid
or vascular biology [58].
3. BASIC PRINCIPLES OF ENDOCANNABINOID-
MEDIATED SYNAPTIC PLASTICITY
One of the most salient features of the nervous system is its
plasticity, including structural and functional changes in in-
dividual neurons and synapses. This characteristic is present
both during brain development and in the adult life. Synap-
tic plasticity allows changes in the strength and number of
synaptic connections between neurons. It is considered as
oneofthemajormechanismsunderlyinglearningandmem-
ory and appears to mediate several other functions in the
central nervous system. The resulting changes in synaptic
eﬃcacy are thought to be crucial in experience-dependent
modiﬁcations of neural function. A closely related concept
is behavioral ﬂexibility that allows an organism to adapt to
variable environmental demands and produce adaptive re-
sponses.
Giventheprominentpresynapticlocalizationofcannabi-
noid CB1 receptors, together with its mainly inhibitory
actions, cannabinoids have been proposed as local retro-
grade modulators, with an important role in modulating es-
sential physiological functions and contributing in diverse
synaptic plasticity phenomena [59–62]. The endocannabi-
noid system seems to aﬀect neuronal excitability participat-
ing in the maintenance of homeostatic conditions in the
brain [26, 63, 64]. In this respect, data obtained from con-
ditional CB1 mutant mice suggest that the endocannabi-
noid system may protect neurons against excessive activ-
ity, and consequently against excitotoxicity. Marsicano et
al. generated conditional mutant mice that lacked expres-
sion of the CB1 receptor in principal forebrain neurons but4 Neural Plasticity
not in adjacent inhibitory interneurons. In mutant mice,
the excitotoxin kainic acid (KA) induced excessive seizures
in vivo, and the threshold to KA-induced neuronal exci-
tation in vitro was severely reduced in their hippocampal
pyramidal neurons. Moreover, KA administration rapidly
raised hippocampal levels of anandamide and induced pro-
tectivemechanismsinwild-typeprincipalhippocampalneu-
rons,whereastheseprotectivemechanismscouldnotbetrig-
gered in mutant mice. These ﬁndings indicate that neu-
ral excitability is increased in CB1-deﬁcient mice and that
the endocannabinoid system may act as a neuroprotec-
tive system against abnormally increased discharge activ-
ity [26, 65]. The CB1 receptor-mediated neuroprotective ef-
fect in the kainate model is apparently mediated by de-
crease of excitability of glutamatergic hippocampal neurons
[48].
Activation of postsynaptic receptors, at diverse neuronal
types, induces the release of endogenous cannabinoid com-
pounds that move backwards across the synapse, until reach-
ing the cannabinoid CB1 receptor, to which they bind, there-
fore inhibiting further neurotransmitter release. Endocanna-
binoid-mediated synaptic plasticity can be transient or long
lasting and can be found at both excitatory and inhibitory
synapses in diverse brain structures. Endocannabinoid-
mediated short-term synaptic plasticity includes two electro-
physiological phenomena, depolarization-induced suppres-
sion of inhibition (DSI), and depolarization-induced sup-
pression of excitation (DSE). DSI is due to a presynaptic
action that reduces GABA release, while DSE results from
presynaptic inhibition of glutamatergic release. There is also
an involvement of the endocannabinoid system in long-term
forms of synaptic plasticity. Long-term potentiation (LTP)
is a long-lasting increase in the strength of a synapse, while
long-term depression (LTD) is a long lasting weakening of
synaptic strength. Both are mechanisms of synaptic plas-
ticity that can persist for hours to weeks and have impor-
tant implications on various forms of learning and memory.
Endocannabinoid-induced long-lasting inhibition of neuro-
transmitter release has been found in diverse brain struc-
tures and at both excitatory and inhibitory synapses (for ex-
haustive discussion of these phenomena, see [15, 26, 64, 66,
67]).
4. EFFECTS OF CANNABINOIDS ON
ANXIETY-RELATED RESPONSES
The main feature of the recreational use of cannabis is that
it produces a euphoriant eﬀect. This “high” can be accom-
panied by decreased anxiety and increased sociability. How-
ever, cannabis can also produce dysphoric reactions, feel-
ings of anxiety, panic, paranoia, and psychosis [68–72]. It is
possible that the reasons for this lie on the bidirectional ef-
fects of cannabinoids on anxiety, with low doses having anx-
iolytic, and high doses having anxiogenic-like eﬀects. The
previous history of the individual and the environmental
context may also critically inﬂuence the induced cannabi-
noid eﬀects. Data from animal models provide further evi-
dence for the complexity of the scenario. Low doses of sev-
eral cannabinoid receptor agonists, nabilone [73], CP 55,940
[74, 75], and Δ9-tetrahydrocannabinol (THC) [76] induced
anxiolytic-like eﬀects in both the elevated plus-maze and
the light-dark box. In contrast, high doses of the cannabi-
noid agonist HU-210 produced anxiogenic-like responses
in the defensive withdrawal test [77] and enhanced emo-
tional responding to tactile stimulation [78], and mid-high
doses of CP 55,940 showed anxiogenic-like eﬀects in the
plus-maze [74, 75, 79, 80] and in the social interaction test
[81].
It has been shown that exposure to chronic stress en-
hances the anxiety-like responsiveness to cannabinoids in
rats [82], a phenomenon that is also observed in humans.
Accordingly, Patel et al. [83] have recently analyzed the in-
teractions between cannabinoids and environmental stress
in the regulation of amygdalar activation in mice. The com-
bination of restraint stress and CB1 agonist administration
produced robust Fos induction within the central amygdala,
indicating a synergistic interaction between environmental
stress and CB1 receptor activation. These data suggest that
the central amygdala could be an important neural substrate
relevant to the context-dependent eﬀects of cannabinoids on
emotional/aﬀective responses.
It is worth noting that, in addition to anxiety, there are
other behavioral responses, such as motor activity and ex-
ploration [75, 80, 81, 84, 85], that are aﬀected by cannabi-
noid agonists in a biphasic manner. In general, low doses
are stimulatory, whereas high doses are inhibitory. Bimodal
eﬀects of cannabinoids might be explained by two distinct
populationsofpresynapticCB1receptors,withdiﬀerentsen-
sitivities to cannabinoids, particularly WIN 55,212-2 (WIN),
located possibly on glutamatergic and GABAergic neurons
[26, 86]. The administration of WIN resulted in a biphasic,
dose-dependent eﬀect on hippocampal acetylcholine (ACh)
release: a low dose and a high dose of the compound induced
a transient stimulation and a prolonged inhibition of hip-
pocampal ACh eﬄux, respectively. These amphidromic re-
sponses appeared to involve the same structural entities, Gi-
coupled CB1 receptors, but diﬀerent neuroanatomical sites.
The low-dose excitatory eﬀectswere mediated in the septum,
whereas the high-dose inhibitory eﬀects were mediated lo-
cally in hippocampus. Moreover, the stimulatory and the in-
hibitory eﬀects of the cannabinoid agonist involved activa-
tion of dopamine D1 and D2 receptors, respectively [7]. Lo-
cal infusion of cannabinoid compounds in speciﬁc brain ar-
eas might be instrumental to identify neural pathways and
neuroanatomically separated CB1 receptor subpopulations
that may play distinct roles and mediate opposing actions
of cannabinoids, notably, anxiolytic versus anxiogenic eﬀects
[87]. This possibility might further explain why elevation
of endocannabinoids levels sometimes has eﬀects that are
diﬀerent from those observed with exogenous cannabinoids
[26]. An additional hypothesis which might account for the
biphasic eﬀects of cannabinoids is the possible diﬀerential
implication of Gs and Gi proteins in the stimulatory and in-
hibitory eﬀects, respectively [88]. It would be interesting to
test this hypothesis in vivo, in relation to anxiety-related ef-
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5. ROLE OF THE ENDOCANNABINOID SYSTEM IN
THE REGULATION OF ANXIETY
5.1. CB1receptorknockoutmice
The development of knockout (KO) mice deﬁcient in
CB1(CB1-KO) receptors has provided an excellent tool to
evaluate the physiological roles of the endocannabinoid sys-
tem, and particularly its possible implication in the regula-
tion of anxiety. The CB1-KO mice showed an increase in the
aggressive response measured in the resident-intruder test
and an anxiogenic-like behavior in the light-dark box, the el-
evated plus-maze test, and the social interaction test [89, 90].
On the other hand, Marsicano et al. [18] did not ﬁnd an
anxiogenic-like response in the plus-maze in their CB1-KO
mice. Discrepancies might be attributed to diﬀerences in the
genetic background of mutant mice, and also to diﬀerences
on baseline anxiety levels and to context-dependent stress
elicited. In particular, CB1-KO mice exclusively showed an
anxiogenic-like behavior under high-stress conditions: light
in the plus-maze and unfamiliar environment in the social
interaction test [18, 89–91]. An impaired action of anxiolytic
drugs,suchasbromazepamandbuspirone,hasbeenalsoob-
served in mutant mice [90]. This latter result suggests that
functional integrity of cannabinoid CB1 receptors is neces-
sary to achieve a complete eﬃcacy of anxiolytic drugs, which
may have consequences in the treatment of mood-related
disorders, including those derived from cannabinoid abuse.
5.2. PharmacologicalblockadeofCB1receptors
Evidence for an endogenous anxiolytic cannabinoid tone
also comes from certain eﬀects of the CB1 receptor antag-
onist rimonabant (SR141716A). This drug has anxiogenic
eﬀects in adult rats submitted to the defensive withdrawal
test and the elevated plus-maze [79, 92]. The cannabinoid
receptor agonist CP 55,940 reduced ultrasonic vocalization
in rat pups separated from their mother, indicating an anx-
iolytic eﬀect, and rimonabant not only reversed this eﬀect,
but also enhanced pup ultrasonic vocalizations when admin-
istered alone [93]. These results further support the view
that there is an endogenous regulation of emotional states
mediated by the cannabinoid system that might be present
since early developmental stages. As for CB1-KO animals,
certain results obtained in mice following rimonabant ad-
ministration showed apparently contradictory results since
this compound was found to be anxiolytic in the plus-maze
[89]. These data may reﬂect species diﬀerences, but it seems
likely that environmental context and baseline anxiety levels
critically account for at least some of the discrepancies ob-
served in the literature. The context dependency is indirectly
supported by the “one-trial sensitization” phenomenon de-
scribed by Rodgers et al. [94] in the plus-maze. In these ex-
periments, the CB1 receptor antagonist had no behavioral
eﬀects in maze-na¨ ıve mice, but induced an anxiolytic-like ef-
fect in the second trial of the test.
Withrespecttorecentclinicaltrials,rimonabanthasbeen
testedforitspossibletherapeuticalapplicationinobesityand
metabolicdisorders,andthemostfrequentadverseeventsre-
sulting in discontinuation of the drug included depression
and anxiety [95–97].
5.3. Inhibitorsofendocannabinoidsinactivation
As indicated above (Section 2), the enzyme FAAH catalyzes
the hydrolysis of the endogenous cannabinoid anandamide.
Pharmacological blockade of this enzyme by URB597 and
URB532producedanxiolytic-likeeﬀectsintheelevatedzero-
maze in adult rats and in the isolation-induced ultrasonic
emission test in rat pups. These eﬀects were accompanied by
augmented brain levels of anandamide and were prevented
by CB1 receptor blockade. Moreover, the anxiolytic actions
of URB597 were not accompanied by typical cannabinoid
signs of intoxication in rodents such as catalepsy or hy-
pothermia. These results indicate that anandamide partic-
ipates in the modulation of emotional states and point to
FAAH inhibition as an innovative approach to antianxiety
therapy [98].
Amodelhasbeenproposedtoexplainthepossiblemech-
anism by which the AEA-CB1 receptor system may par-
ticipate in the control of anxious states. Endocannabinoids
might be generated in the amygdala in response to the anx-
iety inducing stimulus, and would, therefore, regulate emo-
tional states by inﬂuencing amygdala outputs [99]. This view
is supported also by the fact that AEA content in the mouse
basolateral amygdala rises when the animal is conditioned
t oe x p e c taf o o ts h o c ka f t e rh e a r i n gat o n e[ 18]. Thus, the
endocannabinoid system, and AEA in particular, might be
activated in response to anxiogenic situations and this ac-
tivation could be part of a negative feedback system that
limits anxiety [99]. In line with this hypothesis, there are
data suggesting a role of endocannabinoid signaling as an in-
hibitory modulator of behavioral and neuronal responses to
aversive stimuli [13] and in the inhibition of stress-induced
activation of HPA axis [12] (see next section). A recent pa-
per by Patel and Hillard [100] further supports a crucial
role for endocannabinoids in the induction of anxiolytic-
like eﬀects. The inhibitor of endocannabinoids metabolism,
URB597, produceda lineardose-dependent anxiolytic eﬀect.
In turn, AM404 that is considered as an inhibitor of endo-
cannabinoids uptake exerted an action that was more simi-
lar to that elicited by direct agonists, with low doses produc-
ing anxiolytic eﬀects and the highest dose having no eﬀect
[98].ThediﬀerentproﬁlesofAM404mightbeduetothefact
thatinadditiontoincreasingtheendocannabinoid-mediated
tone, this compound can also activate TRV1 receptors [101]
which, as indicated by the study by Marsh et al. quoted above
[57], are also involved in the regulation of anxiety.
Collectively, a majority of evidence suggests the existence
of an anxiolytic endocannabinoid tone. The modulatory role
of the endocannabinoid system against stress is further sup-
ported by studies from Patel et al. [12, 13] indicating that
endocannabinoids act as inhibitory modulators of both neu-
ronal and behavioral activations during an acute stress and
negatively modulate HPA axis activity (see Section 7).6 Neural Plasticity
6. CONDITIONED FEAR RESPONSES, AVERSIVE
MEMORIES, AND FEAR EXTINCTION
Neurobiological substrates of emotional-based learning have
been extensively examined in animal models that allow the
study of acquisition, expression, and retention of Pavlovian
fear conditioning . In this paradigm, an initially innocu-
ous/neutral stimulus (the to-be conditioned stimulus (CS);
e.g., a light, tone, or odor) is paired with an innately aver-
sive unconditioned stimulus (US; e.g., a footshock). Follow-
ing several pairings, the subject comes to exhibit a condi-
tioned fear response to the CS. Conditioned fear behavioral
and physiological responses include changes in heart rate
and blood pressure and freezing or cue-induced fear potenti-
ated startle reﬂex. Excessive fear and anxiety are hallmarks
of a variety of disabling neuropsychiatric disorders. Adap-
tive strategies leading to an appropriate interplay between
fearexpressionandfearextinctionarenecessaryforadequate
coping with aversive encounters. In experimental studies like
the ones mentioned above, fear inhibition is frequently stud-
ied through a procedure in which the previously fear condi-
tioned subject is exposed to the fear-eliciting cue in the ab-
sence of any aversive event. This procedure results in a de-
cline in conditioned fear. In other words, repeated presen-
tation of the conditioned stimulus alone leads to extinction
of the fearful response. There are clear clinical implications
of research on fear extinction. Anxiety- related pathologies
such as phobias and post-traumatic stress disorder (PTSD)
seemtobedisordersoffeardysregulationinwhichinhibition
of fear is absent or insuﬃcient in situations that are patently
safe. In the last years, there is an increasing interest in reveal-
ing the neural mechanisms of fear inhibition, including the
regions in which extinction-related plasticity occurs and the
cellular and molecular processes that are implicated in this
plasticity-related phenomenon (comprehensive reviews on
thesemechanismscanbefoundin[102–105]).Inthepresent
section, we will focus on the possible functional implication
of the endocannabinoid system.
The use of CB1-KO mice and pharmacological block-
ade of CB1 receptors have yielded information regarding
the involvement of the endocannabinoid system in condi-
tioned fear responses. It has been reported that CB1-KO
mice showed strongly impaired short- and long-term ex-
tinction in auditory fear-conditioning tests, with unaﬀected
memory acquisition and consolidation. Consistent with this
ﬁnding, pharmacological blockade of CB1 receptors with ri-
monabant led to a similar deﬁcit in extinction in wild-type
mice [18]. The authors also found that during the extinc-
tion protocol (exposure to the tone alone), the levels of en-
docannabinoids were raised within the basolateral amygdala,
a region known to control extinction of aversive memories,
both in mutant and normal mice. In subsequent studies,
Azad et al. [19] showed that low-frequency stimulation of
aﬀerents in the lateral amygdala released endocannabinoids
postsynaptically from neurons of the basolateral amygdala of
mice, and thereby induced an LTP of inhibitory GABAer-
gic synaptic transmission (LTDi) via a presynaptic mech-
anism. In turn, lowering inhibitory synaptic transmission
signiﬁcantly increased the amplitude of excitatory synaptic
currents in principal neurons of the central nucleus, which
is the main output site of the amygdala. LTDi was blocked
by rimonabant, abolished in CB1-KO animals, and signif-
icantly enhanced in mice lacking FAAH, the anandamide-
degrading enzyme [19]. More recently, it has been addressed
whether CB1 blockade would similarly disrupt extinction in
rats, using fear-potentiated startle as a measure of condi-
tioned fear. The authors further investigated whether phar-
macologic augmentationof CB1activationwouldleadto en-
hancements in extinction. The results indicated that rimona-
bantdose-dependentlyblockedtheextinctionofconditioned
fear in rats, as it does in mice. Moreover, administration of
AM404, an inhibitor of endocannabinoid reuptake, led to a
dose-dependent enhancement in extinction and this eﬀect
was blocked almost completely by rimonabant, indicating
an implication of CB1 receptors. The animals treated with
AM404 also showed decreased shock-induced reinstatement
of fear, suggesting that this compound may reduce suscep-
tibility to reinstatement of fear [106]. Lin et al. [107]h a v e
shown that bilateral infusion of CB1 receptor agonists into
the amygdala after memory reactivation blocked reconsoli-
dation of fear memory measured with fear-potentiated star-
tle. These authors proposed that activation of CB1 receptors
could facilitate extinction on one hand and block reconsoli-
dation on the other.
H¨ olter et al. [108] have compared CB1-KO mice with
their wild-type controls in an appetitively motivated oper-
ant conditioning task including food reward. During the ex-
tinctionphase,whenthepositivereinforcementwasomitted,
control and CB1-KO mice showed a similar decline in accu-
racy of performance and total number of correct responses,
accompaniedbyanincreaseinerrorsofomission[108].Are-
cent pharmacological study using rimonabant [109] further
supports the notion that the cannabinoid CB1 receptor plays
a pivotal role in extinction of aversive memories but is not
essential for extinction of positively reinforced memories.
It has been claimed that fear conditioning in mice com-
bines both associative and non-associative (sensitization)
components and that extinction involves a signiﬁcant habit-
uation component [110]. In a more recent study, Kamprath
et al. [111] have found that CB1-KO mice were severely im-
paired not only in extinction of the fear response to a tone
after fear conditioning, but also in habituation of the fear re-
sponse to a tone after sensitization with an inescapable foot-
shock. Based on these ﬁndings, they have proposed that CB1
receptormightbecriticallyinvolvedinnon-associativelearn-
ing processes (habituation), which would contribute to the
decrease in the fear response. A mouse model has been re-
cently proposed that may allow exploring the role of the en-
docannabinoid system in the associative and non-associative
components of fear has been recently proposed [112].
7. CANNABINOIDS AND THE HYPOTHALAMUS-
PITUITARY-ADRENAL AXIS
An electrophysiological study by Di et al. [20] has revealed
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of glutamate release onto parvocellular neuroendocrine cells
of the hypothalamic paraventricular nucleus (PVN) by stim-
ulating the retrograde release of endocannabinoids that
would subsequently activate presynaptic cannabinoid CB1
receptors. By this mechanism, endocannabinoids may be in-
volved in the modulation of a number of peptidergic sys-
tems, including CRH. Patel et al. [12] have addressed a role
of the endocannabinoid system in the modulation of stress-
induced adrenocortical activity in vivo. These authors con-
ﬁrmed previous studies showing that rimonabant was able
to increase serum corticosterone concentrations under basal
conditions. Moreover, the CB1 receptor antagonist poten-
tiated restraint stress-induced HPA axis activation, whereas
pretreatment of mice with either a low dose of the CB1 re-
ceptor agonist CP 55,940, the endocannabinoid transport
inhibitor AM404, or the FAAH inhibitor URB597 signiﬁ-
cantly decreased or eliminated restraint-induced corticos-
terone release. Acute restraint-induced corticosterone release
was associated with a decrease in hypothalamic 2-AG con-
tent, whereas the attenuation of adrenocortical response ob-
served after prolonged stress was associated with an increase
in hypothalamic 2-AG content. In view of the above data, the
following speculative model can be suggested: during rest-
ing (baseline) conditions, the HPA axis would be tonically
inhibited by endocannabinoids via CB1 receptors located in
the PVN of the hypothalamus. In this way, the endocannabi-
noid system might keep under control the stress response.
Upon an acute stress exposure, that is, when the stress re-
sponse is needed, a reduction of endocannabinoids signal-
ing would allow the HPA axis to be activated (disinhibition).
If the stress becomes chronic, endocannabinoid levels would
increase again to restore a normal homeostasis.
With respect to the eﬀects of exogenous cannabinoid ag-
onists, in general the literature indicates that they exert a
dose-dependent eﬀect on adrenocortical activity with high
doses increasing corticosterone responses [21, 84, 113]. As
previously indicated, high doses of cannabinoids are also
anxiogenic. However, we have found that, at certain doses,
the eﬀects of cannabinoids on anxiety can be dissociated
fromtheireﬀectsonadrenocorticalactivity.Thusahighdose
of the cannabinoid agonist CP 55,940 (75 μg/kg) induced
both, anxiogenic-like eﬀects in the plus-maze and stimu-
lation of adrenocortical activity [80]. However, a dose of
50 μg/kg induced an anxiogenic-like eﬀect in the same test,
without increasing corticosterone concentrations [113].
As in the case of anxiety, literature regarding HPA axis
activity supports the general concept that the pharmacologi-
cal administration of exogenous cannabinoids may lead to a
completely diﬀerent action when compared with the physio-
logicalfunctionsoftheendocannabinoidsystem[26,28,30].
8. ENDOCANNABINOID SYSTEM AND DEPRESSION
Several lines of evidence suggest that the endocannabinoid
system may play a role in the aetiology of depression and
could represent a new therapeutic target for its treatment.
CB1-KO mice showed altered HPA axis function [90]a n da
higher sensitivity to exhibit depressive-like responses in the
chronic unpredictable mild stress procedure, which suggests
an increased susceptibility to develop an anhedonic state
[114]. These characteristics together with their heightened
anxiety [89, 90] and deﬁcits in extinction of aversive mem-
ories [18] have been proposed to be analogous to certain
symptoms of melancholic depression [115].
Several cannabinoid compounds have been evaluated in
behavioral tests such as the forced swimming test (FST)
and the tail-suspension test (TST) that are among the most
widely used screening tests of antidepressant potential of
novel compounds [116]. In the rat FST, administration of
AM404 (endocannabinoid uptake inhibitor) and HU-210, a
potent CB1 receptor agonist, induced decreases in immobil-
ity (indicative of antidepressant activity) that were blocked
by pretreatment with the selective CB1 receptor antago-
nist AM251. The reduction in immobility induced by the
cannabinoid compounds was comparable to that seen with
the reference antidepressant desipramine [117]. In turn, the
FAAH inhibitor URB597 exerted potent antidepressant-like
actions in the mouse TST and the rat FST, and these eﬀects
were prevented or attenuated by rimonabant [118].
During the last years, there has been an active inves-
tigation on the implications of hippocampal neurogenesis
in the pathophysiology and treatment of mood disorders.
Preclinical and clinical studies indicate that stress (possibly
through the action of elevated glucocorticoids) and depres-
sion lead to atrophy and loss of neurons in the adult hip-
pocampus. On the other hand, chronic antidepressant treat-
ment up-regulates hippocampal neurogenesis which could
counteract the stress-induced damage [119, 120]. An ele-
gant study by Jiang et al. [121] revealed an important im-
plication of hippocampal neurogenesis in the antidepres-
sant and anxiolytic-like eﬀects of cannabinoid agonists. They
showedthatbothembryonicandadultrathippocampalneu-
ral stem/progenitor cells were immunoreactive for cannabi-
noid CB1 receptors, indicating that cannabinoids could act
on these receptors to regulate neurogenesis. A chronic (but
not acute) treatment with the potent synthetic cannabi-
noid HU210 promoted neurogenesis in the hippocampal
dentate gyrus of adult rats and exerted anxiolytic- and
antidepressant-like eﬀects. The cannabinoid–induced new-
born neurons appeared to be of functional signiﬁcance, since
X-irradiation of the hippocampus blocked both the neuro-
genic and behavioral eﬀects of chronic HU210 treatment.
These evidences strongly suggest that cannabinoid agonists
might produce anxiolytic- and antidepressant-like eﬀects by
promoting hippocampal neurogenesis. In line with these
ﬁndings, administration of the endocannabinoids uptake in-
hibitor AM404 prior to exposure to predator odor stress in-
hibited both the stress-induced activation of defensive bury-
ingandthesuppressionofcellproliferationinthehippocam-
pus [122], indicating a role for endocannabinoids in the
modulation of stress-induced changes in hippocampal cell
proliferation.
The eﬃcacy of antidepressants has been linked in part to
their ability to reduce the activity of the HPA axis [123]. In
view of the above data, it is tempting to speculate that the8 Neural Plasticity
endocannabinoid system is somehow involved in the action
of currently used antidepressant drugs. In favor of this hy-
pothesis, it has been shown that chronic administration of
the tricyclic antidepressant desipramine resulted in a signiﬁ-
cant increase in the density of the cannabinoid CB1 receptor
in both hippocampus and hypothalamus as well as in a re-
duction in swim stress-induced corticosterone secretion and
immediate early c-fos gene in the medial dorsal parvocellu-
lar region of the PVN of the hypothalamus. Moreover, acute
treatment with the CB1 receptor antagonist AM251 before
exposuretostressoccludedtheeﬀectsofdesipramineoncor-
ticosterone secretion and neuronal activation [124].
9. CONCLUDING REMARKS
During the last few years, the increasing interest in the
link between the endocannabinoid system and emotional re-
sponses has led to a number of interesting data derived from
animal studies. These results may contribute to understand
the complex scenario of cannabinoid eﬀects in humans, and
to clarify the mechanisms underlying associations between
cannabis abuse and mental disorders. Results obtained from
transgenic mice lacking CB1 receptors and by using CB1 re-
ceptors selective antagonists and inhibitors of endocannabi-
noids inactivation suggest the existence of an intrinsic en-
docannabinoid tone which contributes to the regulation of
stress responses and anxiety. An adequate endocannabinoid
function appears to be necessary for adaptive extinction
of aversive memories. The endocannabinoid system might
play a pivotal role in maintaining homeostasis, notably with
regard to physiological and behavioral responses to acute
and prolonged stress. Certain forms of endocannabinoid-
dependent synaptic plasticity have been proposed as crucial
mechanisms subserving these phenomena. Throughout this
review, we have focused on the endocannabinoid system as
a major player in the modulation of synaptic transmission
andplasticityconsideringsolelyinterneuralcommunication.
However, the critical functional role of glial cells in main-
taining a correct brain function and their implications in
diverse neuropathological conditions are now clearly recog-
nized. The new concept of the tripartite synapse in which the
glial cell (notably astrocytes) plays an active role in the mod-
ulation of neurotransmission has recently emerged [125].
Expression of cannabinoid CB1 receptors and endocannabi-
noid synthesis and release have been observed in diﬀerent
types of glial cells [126, 127]. This “glial endocannabinoid
system” may have important physiological and pathological
implications[128,129]anditwouldbeinterestingtoexplore
a possible role in the expression of synaptic plasticity in lim-
bic and extra-limbic regions related to stress, fear, and anxi-
ety responses.
Disregulationormalfunctioningoftheendocannabinoid
system might contribute to the aetiology of anxiety-related
disorders and to certain symptoms of melancholic depres-
sion. In turn, the endocannabinoid system might constitute
an interesting pharmacological target for the development of
anti-anxiety and antidepressant therapies.
The involvement of the endocannabinoid system in the
regulation of anxiety and its participation in the modulation
of behavioral and physiological responses to aversive situa-
tions have other obvious implications. Cannabis abuse may
be one of the causes disrupting the necessary balance for an
appropriate function of the system. There are functional in-
teractions between the endocannabinoid system and other
monoaminergic and peptidergic systems also involved in the
regulation of emotional responses [113, 130]. Thus, the dis-
ruption of the endocannabinoid system as a consequence of
cannabis abuse may alter these other neurochemical systems
contributing to the development of emotional disorders. In
addition to acute aversive emotional reactions to cannabis,
the chronic use of this addictive drug may result in mental
disturbances and neuropsychiatric disorders. In particular,
there are data suggesting that exposure to cannabis deriva-
tivesisassociatedwithahigherriskofschizophrenia,depres-
sion, and anxiety [68–72, 131, 132]. In this review, we have
highlighted the importance of endocannabinoid-based neu-
roplasticity phenomena in the regulation of neuroendocrine
and neurochemical systems implicated in the modulation of
emotional responses and extinction of perseverative behav-
iors and inadaptative aversive memories. Consequently, it is
likely that impairment of endocannabinoid-mediated synap-
tictransmissionandplasticitycontributetotheexpressionof
at least some aspects of these psychiatric illnesses.
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